ClinicalTrials.gg
TerminatedNCT04003623Updated May 10, 2022Results posted

Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)

A Phase 2 interventional study of Pemigatinib in Advanced or Metastatic Solid Tumors, FGFR Mutations and FGFR Translocations, sponsored by Incyte Corporation. Terminated at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-10.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was closed due to lack of enrollment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Neoplasm Metastasis by Incyte Corporation — none open to participants now, none under way, none of them phase 3. Neoplasm Metastasis · Incyte Corporation.

Enrollment
19th of 19
1 · median 70
Started
2019
the only one that year
Phase 2
4 of 19
none open now
Registered
13th of 19
by date

Among the 19 studies in Neoplasm Metastasis by Incyte Corporation, this one is the 19th largest by enrollment, is the only one that started in 2019, is one of 4 in phase 2, and was the 13th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

None of the 19 studies in Neoplasm Metastasis by Incyte Corporation is open now. The open studies under Neoplasm Metastasis, anywhere →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Neoplasm Metastasis by Incyte Corporation as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumors harboring activating FGFR mutations or translocations.

03

Conditions studied

  • Advanced or Metastatic Solid Tumors
  • FGFR Mutations
  • FGFR Translocations

Browse trials for

Keywords

  • Advanced solid tumor
  • metastatic solid tumor
  • FGFR inhibitor
  • FGFR mutation
  • FGFR translocation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed solid tumor that is advanced or (Stage IIIB or IV) or is surgically unresectable.
  • Radiographically (per v1.1 or RANO for primary brain tumors).
  • Documentation of an FGFR1-3 gene mutation or translocation.
  • Objective disease progression after at least 1 prior therapy.
  • Not eligible or able to participate in any other Incyte-sponsored clinical trial.

Exclusion criteria

Exclusion Criteria:

  • Advanced/ bladder cancer or advanced/metastatic cholangiocarcinoma.
  • Prior receipt of a selective FGFR inhibitor.
  • Current evidence of corneal or retinal disorder.
  • History of calcium and phosphate hemostasis disorder or systemic mineral imbalance with ectopic calcification of soft tissues.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Pemigatinib

    Drug: Pemigatinib

Interventions

  • Pemigatinib administered orally once daily.

    Also known as: INCB054828

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Defined as the proportion of participants in each cohort who achieve a complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

    Time frame: Up to approximately 6 months

Secondary outcomes

  1. Progression-free Survival (PFS)

    Defined as the time from first dose until progressive disease (per RECIST v1.1 or Response Assessment in Neuro-Oncology \[RANO\]) or death (whichever is first) in each cohort.

    Time frame: Up to approximately 6 months

  2. Duration of Response (DOR)

    Defined as the time from the date of first assessment of CR or PR until the date of the first progressive disease (per RECIST v1.1 or RANO) or death (whichever is first) in each cohort.

    Time frame: Up to approximately 6 months

  3. Disease Control Rate (DCR)

    Defined as the proportion of participants who achieved best overall response of CR, PR, or stable disease per RECIST v1.1 or RANO.

    Time frame: Up to approximately 6 months

  4. Overall Survival (OS)

    Defined as the time from first dose of study drug to death of any cause in each cohort.

    Time frame: Up to approximately 6 months

  5. Number of Treatment-related Adverse Events

    Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.

    Time frame: Up to approximately 6 months

07

Results

Posted Apr 21, 2022
Limitations and caveats
The Sponsor made a decision unrelated to safety to halt study enrollment. Due to early termination of the study with only1 participant, no analysis of efficacy endpoints was done.

Participant flow

Approximately 50 participants were planned for enrollment. However, only 1 participant was enrolled in the study (assigned to Cohort A) and data was analyzed for safety. The study was closed for lack of enrollment in 2021.

Participant flow — Overall Study
MilestoneCohort A: Participants With FGFR1-3 In-frame Fusions or FGFR2 Intron 17 RearrangementsCohort B: Participants With Known/Predicted Activating Point Mutations in FGFGR1-3
Started10
Completed00
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryObjective Response Rate (ORR)

Defined as the proportion of participants in each cohort who achieve a complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

Time frame:
Up to approximately 6 months

No measurements were reported for this outcome.

SecondaryProgression-free Survival (PFS)

Defined as the time from first dose until progressive disease (per RECIST v1.1 or Response Assessment in Neuro-Oncology \[RANO\]) or death (whichever is first) in each cohort.

Time frame:
Up to approximately 6 months

No measurements were reported for this outcome.

SecondaryDuration of Response (DOR)

Defined as the time from the date of first assessment of CR or PR until the date of the first progressive disease (per RECIST v1.1 or RANO) or death (whichever is first) in each cohort.

Time frame:
Up to approximately 6 months

No measurements were reported for this outcome.

SecondaryDisease Control Rate (DCR)

Defined as the proportion of participants who achieved best overall response of CR, PR, or stable disease per RECIST v1.1 or RANO.

Time frame:
Up to approximately 6 months

No measurements were reported for this outcome.

SecondaryOverall Survival (OS)

Defined as the time from first dose of study drug to death of any cause in each cohort.

Time frame:
Up to approximately 6 months

No measurements were reported for this outcome.

SecondaryNumber of Treatment-related Adverse Events

Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.

Time frame:
Up to approximately 6 months

No measurements were reported for this outcome.

Adverse events

Collected over May 2020 to June 2020. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A: Participants With FGFR1-3 In-frame Fusions or FGFR2 Intron 17 Rearrangements0/1 (0%)0/1 (0%)1/1 (100%)
Cohort B: Participants With Known/Predicted Activating Point Mutations in FGFGR1-3———
Most frequent other events
Most frequent other events
EventCohort A: Participants With FGFR1-3 In-frame Fusions or FGFR2 Intron 17 RearrangementsCohort B: Participants With Known/Predicted Activating Point Mutations in FGFGR1-3
Blurred VisionEye disorders1/1—
DiarrheaGastrointestinal disorders1/1—
FatigueGeneral disorders1/1—
HyperphosphatemiaMetabolism and nutrition disorders1/1—
Lower Back PainMusculoskeletal and connective tissue disorders1/1—
AlopeciaSkin and subcutaneous tissue disorders1/1—

Baseline characteristics

No participants were enrolled in Cohort B.

Age, Categorical
Age, Categorical(Participants)Cohort A: Participants With FGFR1-3 In-frame Fusions or FGFR2 Intron 17 RearrangementsCohort B: Participants With Known/Predicted Activating Point Mutations in FGFGR1-3Total
<=18 years000
Between 18 and 65 years101
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A: Participants With FGFR1-3 In-frame Fusions or FGFR2 Intron 17 RearrangementsCohort B: Participants With Known/Predicted Activating Point Mutations in FGFGR1-3Total
FemaleNA—NA
MaleNA—NA
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort A: Participants With FGFR1-3 In-frame Fusions or FGFR2 Intron 17 RearrangementsCohort B: Participants With Known/Predicted Activating Point Mutations in FGFGR1-3Total
American Indian or Alaska NativeNA—NA
AsianNA—NA
Native Hawaiian or Other Pacific IslanderNA—NA
Black or African AmericanNA—NA
WhiteNA—NA
More than one raceNA—NA
Unknown or Not ReportedNA—NA
08

Study locations

11 sites
  • Compassionate Cancer Care Medical Group
    Fountain Valley, California 92708, United States
  • Ocala Oncology Center
    Ocala, Florida 34474, United States
  • Hawaii Cancer Care
    Honolulu, Hawaii 96813, United States
  • Illinois Cancer Care
    Peoria, Illinois 61615, United States
  • FMH James M Stockman Cancer Institute
    Frederick, Maryland 21702, United States
  • New Jersey Cancer Care and Blood Disorders
    Belleville, New Jersey 07109, United States
  • TriHealth
    Cincinnati, Ohio 45220, United States
  • Sanford Cancer Center
    Sioux Falls, South Dakota 51704, United States
  • Mary Crowley Cancer Center
    Dallas, Texas 75230, United States
  • Oncology Consultants
    Houston, Texas 77030, United States
  • Utah Cancer Specialists
    Salt Lake City, Utah 84106, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Jun 2020, 7 months.

Results were first posted in Apr 2022, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2019
First posted
Jul 1, 2019
StartActual
Oct 31, 2019
Primary completionActual
Jun 12, 2020
CompletionActual
Jun 12, 2020
Results first posted
Apr 21, 2022
Last update
May 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04003623
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Jul 1, 2019
Start date
Oct 31, 2019
Primary completion
Jun 12, 2020
Completion
Jun 12, 2020
Results posted
Apr 21, 2022
Last update
May 10, 2022

Study contacts

Incyte Medical Monitor
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemigatinib

Start the discussion